Catalent extends expansion with $133M deal for Juniper Pharmaceuticals

Money roll
Catalent struck a $133 million deal to buy Juniper Pharmaceuticals. (Pictures of Money/CC BY 2.0)

Somerset, New Jersey-based CDMO Catalent is continuing its investment and expansion campaign, announcing Tuesday that it will buy Juniper Pharmaceuticals for more than $130 million.

Catalent said the deal includes Juniper’s Nottingham, U.K.-based pharma services division, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” Jonathan Arnold, president of Catalent Oral Drug Delivery, said in a statement.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Catalent is paying $11.50 per share for the Boston-based development specialist. Juniper shares closed Monday at $8.70 per share.

Juniper also has contract with Merck KGaA to supply Crinone progesterone gel outside of the United States, an agreement that Catalent will continue. The deal is expected to close this quarter.

RELATED: Catalent doubles down on biologics with $950M deal for Cook Pharmica

This deal follows Catalent’s decision last fall to pay $950 million to buy Cook Pharmica. In that deal, Catalent got Cook’s 875,000-square-foot development and manufacturing facility in in Bloomington, Indiana, along with 750 new employees.

Catalent currently has approximately 11,000 employees, more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue.

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.